Cargando…

Thymoglobulin, interferon-γ and interleukin-2 efficiently expand cytokine-induced killer (CIK) cells in clinical-grade cultures

BACKGROUND: Cytokine-induced killer (CIK) cells are typically differentiated in vitro with interferon (IFN)-γ and αCD3 monoclonal antibodies (mAb), followed by the repeated provision of interleukin (IL)-2. It is presently unknown whether thymoglobulin (TG), a preparation of polyclonal rabbit γ immun...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bonanno, Giuseppina, Iudicone, Paola, Mariotti, Andrea, Procoli, Annabella, Pandolfi, Annino, Fioravanti, Daniela, Corallo, Maria, Perillo, Alessandro, Scambia, Giovanni, Pierelli, Luca, Rutella, Sergio
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3004824/ https://www.ncbi.nlm.nih.gov/pubmed/21138560 http://dx.doi.org/10.1186/1479-5876-8-129

Ejemplares similares

Interleukin-21 induces the differentiation of human umbilical cord blood CD34(-)lineage(- )cells into pseudomature lytic NK cells
por: Bonanno, Giuseppina, et al.
Publicado: (2009)

Effects of pegylated G-CSF on immune cell number and function in patients with gynecological malignancies
por: Bonanno, Giuseppina, et al.
Publicado: (2010)

Cyclooxygenase-2 (COX-2) Inhibition Constrains Indoleamine 2,3-Dioxygenase 1 (IDO1) Activity in Acute Myeloid Leukaemia Cells
por: Iachininoto, Maria Grazia, et al.
Publicado: (2013)

Potency testing of mesenchymal stromal cell growth expanded in human platelet lysate from different human tissues
por: Fazzina, R., et al.
Publicado: (2016)

Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma
por: Bonanno, Giuseppina, et al.
Publicado: (2012)

Pathogen-free, plasma-poor platelet lysate and expansion of human mesenchymal stem cells
por: Iudicone, Paola, et al.
Publicado: (2014)

An avoidable cause of thymoglobulin anaphylaxis
por: Brabant, S., et al.
Publicado: (2017)

Thymoglobulin – new approaches to optimal outcomes
por: Delia Moiceanu, Andreea, et al.
Publicado: (2009)

Cytokine-induced killer (CIK) cells: from basic research to clinical translation
por: Guo, Yelei, et al.
Publicado: (2015)

FOXP3(+) T Regulatory Cell Modifications in Inflammatory Bowel Disease Patients Treated with Anti-TNFα Agents
por: Guidi, Luisa, et al.
Publicado: (2013)

Adoptive Immunotherapy Strategies with Cytokine-Induced Killer (CIK) Cells in the Treatment of Hematological Malignancies
por: Schmeel, Frederic Carsten, et al.
Publicado: (2014)

Cytokine-induced killer (CIK) cell therapy for patients with hepatocellular carcinoma: efficacy and safety
por: Ma, Yue, et al.
Publicado: (2012)

Improving Clinical Manufacturing of IL-15 Activated Cytokine-Induced Killer (CIK) Cells
por: Bremm, Melanie, et al.
Publicado: (2019)

Cytokine-Induced Killer (CIK) Cells, In Vitro Expanded under Good Manufacturing Process (GMP) Conditions, Remain Stable over Time after Cryopreservation
por: Mareschi, Katia, et al.
Publicado: (2020)

Effect and safety of cytokine-induced killer (CIK) cell immunotherapy in patients with breast cancer: A meta-analysis
por: Hu, Jianxin, et al.
Publicado: (2017)

Thymoglobulin induction in heart transplantation: patient selection and implications for maintenance immunosuppression
por: Zuckermann, Andreas, et al.
Publicado: (2015)

In vitro effect of amifostine on haematopoietic progenitors exposed to carboplatin and non-alkylating antineoplastic drugs: haematoprotection acts as a drug-specific progenitor rescue.
por: Pierelli, L., et al.
Publicado: (1998)

In-vitro influence of mycophenolate mofetil (MMF) and Ciclosporin A (CsA) on cytokine induced killer (CIK) cell immunotherapy
por: Bremm, Melanie, et al.
Publicado: (2016)

Adjuvant Chemotherapy With Sequential Cytokine-Induced Killer (CIK) Cells in Stage IB Non-Small Cell Lung Cancer
por: Li, Da-Peng, et al.
Publicado: (2015)

Integrated Antitumor Activities of Cellular Immunotherapy with CIK Lymphocytes and Interferons against KIT/PDGFRA Wild Type GIST
por: Fiorino, Erika, et al.
Publicado: (2022)

CIK Cells and HDAC Inhibitors in Multiple Myeloma
por: Stephan, David, et al.
Publicado: (2017)

Severe Intraoperative Anaphylaxis Related to Thymoglobulin during Living Donor Kidney Transplantation
por: Saeed, Muhammad I., et al.
Publicado: (2020)

Grafalon® vs. Thymoglobulin® as an Induction Agent in Renal Transplantation – A Retrospective Study
por: Jha, Pranaw Kumar, et al.
Publicado: (2021)

CSPG4 CAR-redirected Cytokine Induced Killer lymphocytes (CIK) as effective cellular immunotherapy for HLA class I defective melanoma
por: Giraudo, Lidia, et al.
Publicado: (2023)

Innovative Clinical Perspectives for CIK Cells in Cancer Patients
por: Introna, Martino, et al.
Publicado: (2018)

CD300LG improves the cytotoxic activity of CIK
por: Wang, Qiuyue, et al.
Publicado: (2017)

Acute exercise mobilizes NKT-like cells with a cytotoxic transcriptomic profile but does not augment the potency of cytokine-induced killer (CIK) cells
por: Zúñiga, Tiffany M., et al.
Publicado: (2022)

Engineering tandem CD33xCD146 CAR CIK (cytokine-induced killer) cells to target the acute myeloid leukemia niche
por: Alberti, Gaia, et al.
Publicado: (2023)

A Proposal for Early Dosing Regimens in Heart Transplant Patients Receiving Thymoglobulin and Calcineurin Inhibition
por: Barten, Markus J., et al.
Publicado: (2016)

Feasibility of conditioning with thymoglobulin and reduced intensity TBI to reduce acute GVHD in recipients of allogeneic SCT
por: Toor, A, et al.
Publicado: (2008)

Thymoglobulin Versus Alemtuzumab Versus Basiliximab Kidney Transplantation From Donors After Circulatory Death
por: Asderakis, Argiris, et al.
Publicado: (2022)

Revving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies
por: Pittari, Gianfranco, et al.
Publicado: (2015)

Induction therapy with thymoglobulin or interleukin-2 receptor antagonist for Chinese recipients of living donor renal transplantation: a retrospective study
por: Qiu, Jiang, et al.
Publicado: (2019)

The combination of dendritic cells-cytotoxic T lymphocytes/cytokine-induced killer (DC-CTL/CIK) therapy exerts immune and clinical responses in patients with malignant tumors
por: Wang, Ying, et al.
Publicado: (2015)

Is Thymoglobulin or Rituximab the Cause of This Serum Sickness? A Case Report of Serum Sickness Dilemma and Literature Review
por: Sandhu, Amarpreet, et al.
Publicado: (2012)

Thymoglobulin Induction Dosing Strategies in a Low-Risk Kidney Transplant Population: Three or Four Days?
por: Hardinger, Karen L., et al.
Publicado: (2010)

New Directions for Rabbit Antithymocyte Globulin (Thymoglobulin(®)) in Solid Organ Transplants, Stem Cell Transplants and Autoimmunity
por: Mohty, Mohamad, et al.
Publicado: (2014)

CIK细胞及其在肺癌治疗中的研究进展
Publicado: (2011)

Erratum to: New Directions for Rabbit Antithymocyte Globulin (Thymoglobulin(®)) in Solid Organ Transplants, Stem Cell Transplants and Autoimmunity
por: Mohty, Mohamad, et al.
Publicado: (2014)

First line treatment of aplastic anemia with thymoglobuline in Europe and Asia: Outcome of 955 patients treated 2001‐2012
por: Bacigalupo, Andrea, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_5hi2sf0p3h8r5lpbq69eia26ct